Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 42 min ago
PreprintAll rights reservedbioRxiv

A Novel ACLY Inhibitor Induces Transcriptional and Metabolic Reprogramming to Overcome Tyrosine kinase inhibitor Resistance in Lymphoma

  • N. Pattabiraman
  • C. Lobello
  • D. Rushmore
  • S. Wang
  • L. Mologni
  • H. Borgh
  • K. Nath
  • W. Zhang
  • A. Goldman
  • R. Nejati
  • M. Wasik
  • J. Basappa1
  1. 1Fox chase cancer center
Read full textPDFDOICite

Related

  1. Metabolic-epigenetic coupling between leucine catabolism and glycolysis drives CDK4/6 inhibitor resistance
    M. U. Oliphant, K. Norton, K. Kurmi +8
    bioRxivPreprintCC BY-NCFull textOncologybioRxiv
  2. Longitudinal transcriptomic analysis reveals adaptive transcript usage remodeling associated with PARP inhibitor resistance
    J. Yoo, Y.-N. Kim, Y. Jung +4
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  3. Culture Dimensionality Shapes Drug Sensitivity to Kinase Inhibitor Combinations with Epigenetic or Metabolic Inhibition in a Hepatocellular Carcinoma Model
    Claudia Kunst, Tobias Schilling, Cedric Arling +4
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer.
    Fang Han, Hongjie Du, Kunlin Tian +4
    Cell death & diseasePeer-reviewedCC BYFull textOncologyEurope PMCDOAJ
  5. Serine protease inhibitor from Trichinella spiralis ameliorates diet-induced obesity and adipose tissue inflammation through TIM-3-dependent macrophage reprogramming
    Mingwei Tong, Ge Liu, Guidong Ren +6
    PLOS PathogensPeer-reviewedCC BY 4.0Full textImmunologyPhysiologyPLOS

Cite

BibTeXRIS
BibTeX
@misc{pattabiraman2026novel,
  title = {{A Novel ACLY Inhibitor Induces Transcriptional and Metabolic Reprogramming to Overcome Tyrosine kinase inhibitor Resistance in Lymphoma}},
  author = {N. Pattabiraman and C. Lobello and D. Rushmore and S. Wang and L. Mologni and H. Borgh and K. Nath and W. Zhang and A. Goldman and R. Nejati and M. Wasik and J. Basappa},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.29.755331},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.29.755331v1},
}
RIS
TY  - UNPB
TI  - A Novel ACLY Inhibitor Induces Transcriptional and Metabolic Reprogramming to Overcome Tyrosine kinase inhibitor Resistance in Lymphoma
AU  - N. Pattabiraman
AU  - C. Lobello
AU  - D. Rushmore
AU  - S. Wang
AU  - L. Mologni
AU  - H. Borgh
AU  - K. Nath
AU  - W. Zhang
AU  - A. Goldman
AU  - R. Nejati
AU  - M. Wasik
AU  - J. Basappa
PY  - 2026
DA  - 2026/09/29
PB  - bioRxiv
DO  - 10.64898/2026.09.29.755331
UR  - https://www.biorxiv.org/content/10.64898/2026.09.29.755331v1
ER  -